Literature DB >> 23908387

Stimulants as specific inducers of dopamine-independent σ agonist self-administration in rats.

Takato Hiranita1, Paul L Soto, Gianluigi Tanda, Theresa A Kopajtic, Jonathan L Katz.   

Abstract

A previous study showed that cocaine self-administration induced dopamine-independent reinforcing effects of σ agonists mediated by their selective actions at σ1 receptors (σ1Rs), which are intracellularly mobile chaperone proteins implicated in abuse-related effects of stimulants. The present study assessed whether the induction was specific to self-administration of cocaine. Rats were trained to self-administer the dopamine releaser, d-methamphetamine (0.01-0.32 mg/kg per injection), the μ-opioid receptor agonist, heroin (0.001-0.032 mg/kg per injection), and the noncompetitive N-methyl-d-aspartate receptor/channel antagonist ketamine (0.032-1.0 mg/kg per injection). As with cocaine, self-administration of d-methamphetamine induced reinforcing effects of the selective σ1R agonists PRE-084 [2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate hydrochloride] and (+)-pentazocine (0.032-1.0 mg/kg per injection, each). In contrast, neither self-administration of heroin nor ketamine induced PRE-084 or (+)-pentazocine (0.032-10 mg/kg per injection, each) self-administration. Although the σ1R agonists did not maintain responding in subjects with histories of heroin or ketamine self-administration, substitution for those drugs was obtained with appropriate agonists (e.g., remifentanil, 0.1-3.2 µg/kg per injection, for heroin and (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine ((+)-MK 801; dizocilpine), 0.32-10.0 µg/kg per injection, for ketamine). The σR antagonist N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamine dihydrobromide (BD 1008; 1.0-10 mg/kg) dose-dependently blocked PRE-084 self-administration but was inactive against d-methamphetamine, heroin, and ketamine. In contrast, PRE-084 self-administration was affected neither by the dopamine receptor antagonist (+)-butaclamol (10-100 μg/kg) nor by the opioid antagonist (-)-naltrexone (1.0-10 mg/kg), whereas these antagonists were active against d-methamphetamine and heroin self-administration, respectively. The results indicate that experience specifically with indirect-acting dopamine agonists induces reinforcing effects of previously inactive σ1R agonists. It is further suggested that induced σ1R reinforcing mechanisms may play an essential role in treatment-resistant stimulant abuse, suggesting new approaches for the development of effective medications for its treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23908387      PMCID: PMC3781409          DOI: 10.1124/jpet.113.207522

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  50 in total

1.  Pharmacotherapy and other treatments for cocaine abuse and dependence.

Authors:  Frank J Vocci; Ahmed Elkashef
Journal:  Curr Opin Psychiatry       Date:  2005-05       Impact factor: 4.741

2.  Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls.

Authors:  Roman Stefanski; Zuzana Justinova; Teruo Hayashi; Minoru Takebayashi; Steven R Goldberg; Tsung-Ping Su
Journal:  Psychopharmacology (Berl)       Date:  2004-03-17       Impact factor: 4.530

3.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

Authors:  G Tanda; F E Pontieri; G Di Chiara
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

4.  Protein kinase A activation down-regulates, whereas extracellular signal-regulated kinase activation up-regulates sigma-1 receptors in B-104 cells: Implication for neuroplasticity.

Authors:  Gianfrancesco Cormaci; Tomohisa Mori; Teruo Hayashi; Tsung-Ping Su
Journal:  J Pharmacol Exp Ther       Date:  2006-10-18       Impact factor: 4.030

5.  Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.

Authors:  Gregory T Collins; Jeffrey M Witkin; Amy H Newman; Kjell A Svensson; Peter Grundt; Jianjing Cao; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-04-15       Impact factor: 4.030

6.  Comparison of binding parameters of sigma 1 and sigma 2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes.

Authors:  V H Nguyen; M Kassiou; G A Johnston; M J Christie
Journal:  Eur J Pharmacol       Date:  1996-09-12       Impact factor: 4.432

7.  Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and σ receptors.

Authors:  Takato Hiranita; Paul L Soto; Stephen J Kohut; Theresa Kopajtic; Jianjing Cao; Amy H Newman; Gianluigi Tanda; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2011-08-22       Impact factor: 4.030

Review 8.  Medication development for addictive disorders: the state of the science.

Authors:  Frank J Vocci; Jane Acri; Ahmed Elkashef
Journal:  Am J Psychiatry       Date:  2005-08       Impact factor: 18.112

Review 9.  The pharmacology of sigma-1 receptors.

Authors:  Tangui Maurice; Tsung-Ping Su
Journal:  Pharmacol Ther       Date:  2009-07-18       Impact factor: 12.310

10.  Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors.

Authors:  Takato Hiranita; Paul L Soto; Amy H Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2009-02-19       Impact factor: 4.030

View more
  19 in total

1.  Methamphetamine Induces Dopamine Release in the Nucleus Accumbens Through a Sigma Receptor-Mediated Pathway.

Authors:  David M Hedges; J Daniel Obray; Jordan T Yorgason; Eun Young Jang; Vajira K Weerasekara; Joachim D Uys; Frederick P Bellinger; Scott C Steffensen
Journal:  Neuropsychopharmacology       Date:  2017-11-29       Impact factor: 7.853

2.  σ Receptor Effects of N-Substituted Benztropine Analogs: Implications for Antagonism of Cocaine Self-Administration.

Authors:  Takato Hiranita; Weimin C Hong; Theresa Kopajtic; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2017-04-25       Impact factor: 4.030

Review 3.  Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

Authors:  Gerard Sanacora; Alan F Schatzberg
Journal:  Neuropsychopharmacology       Date:  2014-09-26       Impact factor: 7.853

4.  Potential Molecular Mechanisms on the Role of the Sigma-1 Receptor in the Action of Cocaine and Methamphetamine.

Authors:  Yuko Yasui; Tsung-Ping Su
Journal:  J Drug Alcohol Res       Date:  2016-02-20

5.  Identification of Antagonists Selective for Sigma Receptor Subtypes that are Active In vivo.

Authors:  Takato Hiranita
Journal:  J Alcohol Drug Depend       Date:  2016-07-11

6.  Effects of environmental enrichment on self-administration of the short-acting opioid remifentanil in male rats.

Authors:  Rebecca S Hofford; Jonathan J Chow; Joshua S Beckmann; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2017-09-15       Impact factor: 4.530

Review 7.  The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.

Authors:  Danielle O Sambo; Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Pharmacol Ther       Date:  2018-01-31       Impact factor: 12.310

Review 8.  A role for sigma receptors in stimulant self-administration and addiction.

Authors:  Jonathan L Katz; Weimin C Hong; Takato Hiranita; Tsung-Ping Su
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

9.  Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats.

Authors:  Takato Hiranita; Stephen J Kohut; Paul L Soto; Gianluigi Tanda; Theresa A Kopajtic; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2013-11-05       Impact factor: 4.030

10.  Blockade of Cocaine or σ Receptor Agonist Self Administration by Subtype-Selective σ Receptor Antagonists.

Authors:  Jonathan L Katz; Takato Hiranita; Theresa A Kopajtic; Kenner C Rice; Christophe Mesangeau; Sanju Narayanan; Ahmed H Abdelazeem; Christopher R McCurdy
Journal:  J Pharmacol Exp Ther       Date:  2016-04-21       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.